ursodeoxycholic acid has been researched along with Diseases, Metabolic in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deeb, M; Hirschfield, GM; Leung, KK | 1 |
| Chen, T; Cheng, L; Guo, M; Li, B; Liu, J; Liu, P; Qiao, X; She, J; Wei, Y; Wu, Y; Xi, W; Yuan, Z; Zhou, J | 1 |
| Gong, JY; Lu, Y; Setchell, KD; Wang, JS; Zhang, MH; Zhao, J | 1 |
| Claudel, T; Fickert, P; Fuchs, C; Halilbasic, E; Hofer, H; Kazemi-Shirazi, L; Kienbacher, C; Krones, E; Moustafa, T; Munda, P; Paumgartner, G; Pollheimer, M; Steinacher, D; Trauner, M; Traussnigg, S | 1 |
| Halilbasic, E; Steinacher, D; Trauner, M | 1 |
3 review(s) available for ursodeoxycholic acid and Diseases, Metabolic
| Article | Year |
|---|---|
Review article: pathophysiology and management of primary biliary cholangitis.
Topics: Fatigue; Humans; Liver Cirrhosis, Biliary; Liver Transplantation; Metabolic Diseases; Pruritus; Ursodeoxycholic Acid | 2020 |
Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders.
Topics: Animals; Bile Duct Diseases; Humans; Liver Diseases; Metabolic Diseases; Signal Transduction; Ursodeoxycholic Acid | 2015 |
Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases.
Topics: Animals; Cholestasis; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Liver Diseases; Metabolic Diseases; Ursodeoxycholic Acid | 2017 |
2 other study(ies) available for ursodeoxycholic acid and Diseases, Metabolic
| Article | Year |
|---|---|
Glycoursodeoxycholic acid ameliorates diet-induced metabolic disorders with inhibiting endoplasmic reticulum stress.
Topics: Animals; Diet, High-Fat; Endoplasmic Reticulum Stress; Fatty Liver; Female; Humans; Lipid Metabolism; Liver; Male; Metabolic Diseases; Middle Aged; Obesity; Ursodeoxycholic Acid | 2021 |
Δ4-3-oxosteroid-5β-reductase deficiency: Responses to oral bile acid therapy and long-term outcomes.
Topics: Administration, Oral; Chenodeoxycholic Acid; Disease Progression; DNA Mutational Analysis; Dose-Response Relationship, Drug; Female; Gastrointestinal Agents; Humans; Infant, Newborn; Male; Metabolic Diseases; Mutation; Oxidoreductases; Retrospective Studies; Treatment Outcome; Ursodeoxycholic Acid | 2019 |